Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study
- PMID: 31009939
- PMCID: PMC6829283
- DOI: 10.7326/M18-1605
Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study
Erratum in
-
Correction: Long-Term Weight Loss With Metformin or Lifestyle Intervention in the Diabetes Prevention Program Outcomes Study.Ann Intern Med. 2020 Sep 15;173(6):508. doi: 10.7326/L20-0029. Ann Intern Med. 2020. PMID: 32926818 No abstract available.
Abstract
Background: Identifying reliable predictors of long-term weight loss (LTWL) could lead to improved weight management.
Objective: To identify some predictors of LTWL.
Design: The DPP (Diabetes Prevention Program) was a randomized controlled trial that compared weight loss with metformin, intensive lifestyle intervention (ILS), or placebo. Its Outcomes Study (DPPOS) observed patients after the masked treatment phase ended. (ClinicalTrials.gov: NCT00004992 and NCT00038727).
Setting: 27 DPP and DPPOS clinics.
Participants: Of the 3234 randomly assigned participants, 1066 lost at least 5% of baseline weight in the first year and were followed for 15 years.
Measurements: Treatment assignment, personal characteristics, and weight.
Results: After 1 year, 289 (28.5%) participants in the metformin group, 640 (62.6%) in the ILS group, and 137 (13.4%) in the placebo group had lost at least 5% of their weight. After the masked treatment phase ended, the mean weight loss relative to baseline that was maintained between years 6 and 15 was 6.2% (95% CI, 5.2% to 7.2%) in the metformin group, 3.7% (CI, 3.1% to 4.4%) in the ILS group, and 2.8% (CI, 1.3% to 4.4%) in the placebo group. Independent predictors of LTWL included greater weight loss in the first year in all groups, older age and continued metformin use in the metformin group, older age and absence of either diabetes or a family history of diabetes in the ILS group, and higher fasting plasma glucose levels at baseline in the placebo group.
Limitation: Post hoc analysis; examination of nonrandomized subsets of randomized groups after year 1.
Conclusion: Among persons with weight loss of at least 5% after 1 year, those originally randomly assigned to metformin had the greatest loss during years 6 to 15. Older age and the amount of weight initially lost were the most consistent predictors of LTWL maintenance.
Primary funding source: National Institutes of Health.
Figures


Comment in
-
Advising Patients on How to Achieve Long-Term Weight Loss.Ann Intern Med. 2019 May 21;170(10):724-725. doi: 10.7326/M19-0782. Epub 2019 Apr 23. Ann Intern Med. 2019. PMID: 31009940 No abstract available.
Similar articles
-
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study.Lancet. 2009 Nov 14;374(9702):1677-86. doi: 10.1016/S0140-6736(09)61457-4. Epub 2009 Oct 29. Lancet. 2009. PMID: 19878986 Free PMC article. Clinical Trial.
-
Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study.Diabetologia. 2017 Sep;60(9):1601-1611. doi: 10.1007/s00125-017-4361-9. Epub 2017 Aug 2. Diabetologia. 2017. PMID: 28770322 Free PMC article. Review.
-
Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.Lancet. 2012 Jun 16;379(9833):2243-51. doi: 10.1016/S0140-6736(12)60525-X. Epub 2012 Jun 9. Lancet. 2012. PMID: 22683134 Free PMC article. Clinical Trial.
-
Long-term effects of lifestyle and metformin interventions in DPP on bone density.Osteoporos Int. 2021 Nov;32(11):2279-2287. doi: 10.1007/s00198-021-05989-1. Epub 2021 Jun 4. Osteoporos Int. 2021. PMID: 34086101 Free PMC article. Clinical Trial.
-
[Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations].Invest Clin. 1997 Mar;38(1):39-52. Invest Clin. 1997. PMID: 9235072 Review. Spanish.
Cited by
-
Effect of liraglutide treatment on body mass index and weight parameters in children and adolescents with type 2 diabetes: Post hoc analysis of the ellipse trial.Pediatr Obes. 2021 Aug;16(8):e12778. doi: 10.1111/ijpo.12778. Epub 2021 Feb 25. Pediatr Obes. 2021. PMID: 33634589 Free PMC article. Clinical Trial.
-
Long-Term Use of Metformin and Vitamin B12 Deficiency in Diabetes.Curr Drug Saf. 2025;20(3):258-270. doi: 10.2174/0115748863308106240816044733. Curr Drug Saf. 2025. PMID: 39206482 Review.
-
Diet quality, weight loss, and diabetes incidence in the Diabetes Prevention Program (DPP).BMC Nutr. 2020 Dec 15;6(1):74. doi: 10.1186/s40795-020-00400-4. BMC Nutr. 2020. PMID: 33317629 Free PMC article.
-
Lower Adherence to a Mediterranean Diet Is Associated with High Adiposity in Community-Dwelling Older Adults: Results from the Longevity Check-Up (Lookup) 7+ Project.Nutrients. 2023 Nov 23;15(23):4892. doi: 10.3390/nu15234892. Nutrients. 2023. PMID: 38068751 Free PMC article.
-
Sarcopenic obesity: emerging mechanisms and therapeutic potential.Metabolism. 2023 Sep;146:155639. doi: 10.1016/j.metabol.2023.155639. Epub 2023 Jun 26. Metabolism. 2023. PMID: 37380015 Free PMC article. Review.
References
-
- Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(Suppl 2):S102–S38. - PMC - PubMed
-
- Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- U01 DK048412/DK/NIDDK NIH HHS/United States
- U01 DK048375/DK/NIDDK NIH HHS/United States
- U01 DK048434/DK/NIDDK NIH HHS/United States
- U01 DK048413/DK/NIDDK NIH HHS/United States
- R01 DK078907/DK/NIDDK NIH HHS/United States
- U54 GM104940/GM/NIGMS NIH HHS/United States
- M01 RR016587/RR/NCRR NIH HHS/United States
- U01 DK048339/DK/NIDDK NIH HHS/United States
- U01 DK048443/DK/NIDDK NIH HHS/United States
- U01 DK048400/DK/NIDDK NIH HHS/United States
- U01 DK048468/DK/NIDDK NIH HHS/United States
- U01 DK048404/DK/NIDDK NIH HHS/United States
- U01 DK048407/DK/NIDDK NIH HHS/United States
- U01 DK048437/DK/NIDDK NIH HHS/United States
- U01 DK048406/DK/NIDDK NIH HHS/United States
- U01 DK048397/DK/NIDDK NIH HHS/United States
- U01 DK048381/DK/NIDDK NIH HHS/United States
- U01 DK048514/DK/NIDDK NIH HHS/United States
- U01 DK048485/DK/NIDDK NIH HHS/United States
- U01 DK048489/DK/NIDDK NIH HHS/United States
- U01 DK048349/DK/NIDDK NIH HHS/United States
- U01 DK048377/DK/NIDDK NIH HHS/United States
- P30 DK017047/DK/NIDDK NIH HHS/United States